Free Trial

Grail Q2 2024 Earnings Report

Grail logo
$31.20 -0.93 (-2.89%)
As of 03/25/2025 04:00 PM Eastern

Grail EPS Results

Actual EPS
-$5.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Grail Revenue Results

Actual Revenue
$31.97 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grail Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Grail Earnings Headlines

Grail price target raised to $20 from $16 at Morgan Stanley
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Why Grail (GRAL) Is Falling Today
See More Grail Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grail? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grail and other key companies, straight to your email.

About Grail

Grail (NASDAQ:GRAL) is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

View Grail Profile

More Earnings Resources from MarketBeat